Mckesson Corp

MCK

711.420USD

-8.850-1.23%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

17 / 176

Overall Ranking

112 / 4724

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 18 analysts

Buy

Current Rating

785.731

Target Price

+10.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

McKesson Corporation is a provider of diversified healthcare services. It is engaged in advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over the counter (OTC) pharmaceutical drugs and other healthcare-related products in the United States. Its Prescription Technology Solutions segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Its Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies. Its International segment includes its operations in Norway, which provides distribution and services to wholesale and retail customers.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 359.05B.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 29.76% year-on-year.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 10.68%.

Overvalued

The company’s latest PE is 28.35, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 111.75M shares, decreasing 2.40% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 12.01M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.19.

The company's current financial score is 7.53, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 90.82B, representing a year-over-year increase of 18.95%, while its net profit experienced a year-over-year increase of 59.29%.

Score

Industry at a Glance

Previous score

7.53

Change

0



Financials

8.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.49

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

3.14

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.98

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 27.24, which is -2.09% below the recent high of 26.67 and 34.39% above the recent low of 17.87.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 17/176

No Data

The company’s current earnings forecast score is 8.35, which is higher than the Pharmaceuticals industry's average of 7.96. The average price target for Mckesson Corp is 800.00, with a high of 830.00 and a low of 750.00.

Score

Industry at a Glance

Previous score

8.33

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.04, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 721.34 and the support level at 641.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.54

Change

-0.33

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 89.83%, representing a quarter-over-quarter decrease of 0.66%. The largest institutional shareholder is The Vanguard, holding a total of 12.01M shares, representing 9.66% of shares outstanding, with 2.89% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

11.78M

-0.37%

BlackRock Institutional Trust Company, N.A.

6.57M

-0.23%

State Street Global Advisors (US)

5.69M

-0.30%

MFS Investment Management

4.54M

-2.65%

JP Morgan Asset Management

3.07M

-2.85%

Geode Capital Management, L.L.C.

2.71M

+1.70%

Putnam Investment Management, L.L.C.

2.43M

+4.08%

Fidelity Management & Research Company LLC

1.37M

-34.86%

Norges Bank Investment Management (NBIM)

2.11M

-7.75%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 6.72, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Mckesson Corp

MCK

6.94 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

7.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cardinal Health Inc

CAH

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.